COVID-19 mRNA vaccines: Platforms and current developments
GT Szabó, AJ Mahiny, I Vlatkovic - Molecular Therapy, 2022 - cell.com
Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
Nanoscale delivery platforms for RNA therapeutics: challenges and the current state of the art
LH Rhym, DG Anderson - Med, 2022 - cell.com
RNA nanomedicines present a promising class of therapeutics, with broad applications in
protein replacement therapy, gene editing, immunotherapy, and vaccines, owing to their …
protein replacement therapy, gene editing, immunotherapy, and vaccines, owing to their …
Pre-validation of a novel reconstructed skin equivalent model for skin irritation and nanoparticle risk assessment
P Sanches, R Bizon, GG Alves, CM Catarino… - Nanoscale …, 2025 - pubs.rsc.org
In alignment with the global movement toward reducing animal testing, several
reconstructed human epidermis (RHE) models have been created for conducting skin …
reconstructed human epidermis (RHE) models have been created for conducting skin …
早产儿支气管肺发育不良发病机制相关因子的研究进展
陈蕙卉， 李秋平， 边佳昕， 孙冬梅 - 发育医学电子杂志, 2024 - fyyxzz.com
早产儿支气管肺发育不良发病机制相关因子的研究进展 Page 1 ·296· 《发育医学电子杂志》2024
年7 月第12 卷第4 期J Dev Med (Electronic Version), Jul. 2024, Vol.12, No.4 早产儿支气管肺 …
年7 月第12 卷第4 期J Dev Med (Electronic Version), Jul. 2024, Vol.12, No.4 早产儿支气管肺 …